Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
In the last year, many AbbVie Inc. (NYSE:ABBV) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually ...
Results that may be inaccessible to you are currently showing.